Physician profile
Kelly Tabor
NPI 1467903872
$13,438.17
in general payments reported to CMS, 2019-2025
37 companies · $3,857 in 2025
The $3,857 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,190 · 2022: $2,190 · 2023: $2,913 · 2024: $2,287 · 2025: $3,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,102 · Travel and Lodging: $896 · Education: $58.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,102.23 |
| Travel and Lodging | $896.31 |
| Education | $58.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,049.78 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,989.45 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,502.69 | 2021-2025 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Inspire Medical Systems, INC. | $1,219.66 | 2023-2025 | Inspire |
| Genzyme Corporation | $1,108.49 | 2021-2025 | |
| Grifols USA, LLC | $913.68 | 2021-2025 | Prolastin-C Liquid |
| Insmed, INC. | $824.97 | 2021-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $770.96 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $421.46 | 2022-2024 | Yupelri |
| United Therapeutics Corporation | $280.98 | 2021-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $242.44 | 2022-2023 | Glassia |
| Jazz Pharmaceuticals INC. | $210.19 | 2021-2025 | |
| Viatris Specialty LLC | $206.85 | 2025 | Yupelri |
| Verona Pharma, INC. | $198.50 | 2025 | Ohtuvayre |
| Amgen INC. | $176.43 | 2022-2025 | Tezspire |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $155.29 | 2021-2022 | |
| Baxter Healthcare | $154.28 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Hospital Products INC. | $124.44 | 2021-2023 | Acthar |
| Actelion Pharmaceuticals US, INC. | $111.05 | 2021-2022 | |
| Electromed, INC. | $102.79 | 2023-2024 | Smartvest |
| Harmony Biosciences LLC | $93.09 | 2022-2023 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $92.47 | 2023-2024 | Lumryz |
| Sanofi-Aventis U.S. LLC | $77.00 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $59.29 | 2022-2023 | Belsomra |
| Genentech USA, INC. | $58.62 | 2021-2023 | Xolair |
| Janssen Pharmaceuticals, INC | $43.50 | 2022-2023 | Xarelto |
| Hikma Pharmaceuticals USA | $33.65 | 2023-2025 | Ryaltris |
| Gilead Sciences, INC. | $31.02 | 2021-2022 | |
| Tactile Systems Technology INC | $30.97 | 2025 | Flexitouch Plus, Nimbl |
| Advanced Respiratory, INC | $26.12 | 2021 | |
| Fisher & Paykel Healthcare INC | $25.46 | 2023 | Fisher & Paykel Healthcare |
| Optinose US, INC. | $20.58 | 2021 | |
| Phadia US INC. | $19.16 | 2023 | Immunocap |
| Azurity Pharmaceuticals, INC. | $17.41 | 2025 | Alvesco |
| Lilly USA, LLC | $16.23 | 2025 | Zepbound |
| Idorsia Pharmaceuticals US INC | $15.43 | 2024 | Quviviq |
| Inogen, INC. | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Tabor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.